AstraZeneca (AZNCF) News Today $146.74 +6.11 (+4.34%) As of 05/2/2025 03:46 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period AZNCF Makes Bullish Cross Above Critical Moving AverageMay 2 at 10:43 PM | nasdaq.comAstraZeneca’s triple-combo triumphs in two Phase III asthma trialsMay 2 at 12:41 PM | finance.yahoo.comAstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trialsMay 2 at 12:41 PM | msn.comAstraZeneca asthma drug meets targets in phase 3 trialsMay 2 at 7:40 AM | lse.co.ukAstraZeneca's Breztri meets main goals of late-stage asthma trialsMay 2 at 2:34 AM | reuters.comImfinzi approval positions AstraZeneca at forefront of perioperative MIBCApril 30, 2025 | finance.yahoo.comAstraZeneca CFO Talks Tariffs, Forward Guidance, EarningsApril 30, 2025 | bloomberg.comAstraZeneca’s Soriot Warns US Against Trade Tariffs on MedicinesApril 29, 2025 | msn.comAstraZeneca has built resilient supply chains in the U.S. and China for years, doesn't expect much tariff impact, CEO saysApril 29, 2025 | msn.comAstraZeneca discontinues Truqap trial in castration-resistant prostate cancerApril 29, 2025 | msn.comAstraZeneca outlines $5B opportunity for oral PCSK9 inhibitor with Phase 3 trials in 2025April 29, 2025 | msn.comAstraZeneca's 'number 1 priority' is the US, CEO saysApril 29, 2025 | finance.yahoo.comAstraZeneca says potential US tariffs manageable, faces another China fineApril 29, 2025 | msn.comAstraZeneca CEO: Trump tariffs 'not material long term'April 29, 2025 | msn.comAstraZeneca doubles down on US manufacturing amid tariff threatApril 29, 2025 | msn.comAstraZeneca says potential US tariffs manageable; faces another China fineApril 29, 2025 | msn.comAstraZeneca affirms commitment to US manufacturing as profits riseApril 29, 2025 | ft.comAstraZeneca pushes EU to spend more on drugs amid Trump tariffs threatApril 25, 2025 | finance.yahoo.comAstraZeneca Earnings Expected to Rise With Focus on China -- Earnings PreviewApril 25, 2025 | marketwatch.comThe Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICSApril 25, 2025 | finance.yahoo.comAstraZeneca CEO says Europe must invest more to protect its 'health sovereignty'April 24, 2025 | msn.comNew AstraZeneca breast cancer drug shows 'meaningful improvement' in survivability ratesApril 23, 2025 | msn.comAstraZeneca rallies Monday, outperforms marketApril 14, 2025 | marketwatch.comAstraZeneca’s oral breast cancer drug Truqap greenlit for NHS useApril 12, 2025 | msn.comBernstein Sticks to Its Buy Rating for AstraZeneca (AZN)April 9, 2025 | markets.businessinsider.comAstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAYApril 9, 2025 | uk.finance.yahoo.comDaiichi Sankyo and AstraZeneca secure EU approval for DatrowayApril 9, 2025 | lse.co.ukAstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapyApril 8, 2025 | finance.yahoo.comAstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical TrialApril 7, 2025 | msn.comAstraZeneca slides Monday, underperforms marketApril 7, 2025 | marketwatch.comEC approves AstraZeneca’s Imfinzi combo for NSCLCApril 7, 2025 | finance.yahoo.comAstraZeneca gets EU approval for cancer treatments Enhertu and ImfinziApril 4, 2025 | lse.co.ukAstraZeneca (AZN) Receives a Buy from UBSApril 1, 2025 | markets.businessinsider.comAstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trialApril 1, 2025 | finance.yahoo.comFDA approves AstraZeneca’s Imfinzi combo for bladder cancerApril 1, 2025 | finance.yahoo.comAstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA ApprovalMarch 31, 2025 | marketwatch.comAstraZeneca’s Calquence recommended for approval in EU for treatment of MCLMarch 31, 2025 | markets.businessinsider.comAstraZeneca’s Imfinzi approved in US for treatment of adults with MIBCMarch 31, 2025 | markets.businessinsider.comAstraZeneca’s potential blockbuster pill halves high cholesterolMarch 31, 2025 | detroitnews.comHarbour BioMed Shares Soar on News of AstraZeneca CollaborationMarch 24, 2025 | marketwatch.comAstraZeneca to invest $2.5bn in R&D centre in ChinaMarch 24, 2025 | finance.yahoo.comAstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probesMarch 22, 2025 | msn.comAstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probeMarch 22, 2025 | msn.comAstraZeneca to invest USD2.5 billion in new Beijing strategic centreMarch 21, 2025 | lse.co.ukAstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIMarch 18, 2025 | finance.yahoo.comAstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy PortfolioMarch 18, 2025 | msn.comAstraZeneca and Alteogen agree on ALT-B4 platform techMarch 18, 2025 | finance.yahoo.comAstraZeneca to acquire EsoBiotec for $425M upfrontMarch 17, 2025 | markets.businessinsider.comAstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buyMarch 17, 2025 | msn.comAstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambitionMarch 17, 2025 | msn.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.030.72▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼175▲AZNCF Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today Anew Medical News Today Arno Therapeutics News Today AVAX Technologies News Today BriaCell Therapeutics News Today Cannabis Global News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AZNCF Stock Free AZNCF Stock Alerts